Teva Continues Divestitures To Close Allergan Deal With Product Sale To Impax
This article was originally published in The Pink Sheet Daily
Executive Summary
Impax will gain 15 approved generics and three pipeline assets, which will help offset lower revenues of two of its existing top-sellers.
You may also be interested in...
Impax CEO’s Strategy: Aggressive BD, Restructure R&D And Cut Costs
Since Impax Laboratories’ CEO Wilkinson took the helm in April, the company has completed several significant deals and most recently restructured R&D to deliver savings, but a successful turnaround will require resolving outstanding manufacturing issues.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.